

University of Groningen

Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma

Hartleben, Götz; Müller, Christine; Krämer, Andreas; Schimmel, Heiko; Zidek, Laura M; Dornblut, Carsten; Winkler, René; Eichwald, Sabrina; Kortman, Gertrud; Kosan, Christian

Published in:
The EMBO Journal

DOI:
[10.15252/embj.201798589](https://doi.org/10.15252/embj.201798589)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Hartleben, G., Müller, C., Krämer, A., Schimmel, H., Zidek, L. M., Dornblut, C., Winkler, R., Eichwald, S., Kortman, G., Kosan, C., Kluiver, J., Petersen, I., van den Berg, A., Wang, Z-Q., & Calkhoven, C. F. (2018). Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma. *The EMBO Journal*, 37(21), [98589]. <https://doi.org/10.15252/embj.201798589>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma

Götz Hartleben^{1,2}, Christine Müller^{1,2}, Andreas Krämer², Heiko Schimmel³, Laura M Zidek², Carsten Dornblut², René Winkler⁴, Sabrina Eichwald², Gertrud Kortman¹, Christian Kosan⁴ , Joost Kluiver⁵, Iver Petersen³, Anke van den Berg⁵, Zhao-Qi Wang² & Cornelis F Calkhoven^{1,2,*}

Abstract

The tuberous sclerosis complex (TSC) 1/2 is a negative regulator of the nutrient-sensing kinase mechanistic target of rapamycin complex (mTORC1), and its function is generally associated with tumor suppression. Nevertheless, biallelic loss of function of TSC1 or TSC2 is rarely found in malignant tumors. Here, we show that TSC1/2 is highly expressed in Burkitt's lymphoma cell lines and patient samples of human Burkitt's lymphoma, a prototypical MYC-driven cancer. Mechanistically, we show that MYC induces TSC1 expression by transcriptional activation of the TSC1 promoter and repression of miR-15a. TSC1 knockdown results in elevated mTORC1-dependent mitochondrial respiration enhanced ROS production and apoptosis. Moreover, TSC1 deficiency attenuates tumor growth in a xenograft mouse model. Our study reveals a novel role for TSC1 in securing homeostasis between MYC and mTORC1 that is required for cell survival and tumor maintenance in Burkitt's lymphoma. The study identifies TSC1/2 inhibition and/or mTORC1 hyperactivation as a novel therapeutic strategy for MYC-driven cancers.

Keywords Burkitt's lymphoma; cancer; mTORC1; MYC; TSC1/2

Subject Categories Cancer; Signal Transduction

DOI 10.15252/emboj.201798589 | Received 7 November 2017 | Revised 29 June 2018 | Accepted 30 August 2018 | Published online 20 September 2018

The EMBO Journal (2018) 37: e98589

Introduction

TSC1/2 is a critical upstream regulator of the mechanistic target of rapamycin complex (mTORC) 1 kinase. TSC1 (hamartin) stabilizes TSC2 (tuberin), which is the GTPase-activating protein (GAP) for Rheb (Ras homolog enriched in brain) in the regulation of mTORC1 (Mieulet & Lamb, 2010). Germline mutations in either TSC1 or TSC2 result in the development of benign tumors (hamartomas) due to hyperactive mTORC1 signaling, which, however, usually does not

result in malignancy. Moreover, loss of function of either TSC1 or TSC2 is rarely found in malignant tumors (Mieulet & Lamb, 2010) with some known exceptions like somatic mutations of TSC1 in bladder cancer (Pymar *et al*, 2008) or TSC2 in hepatocellular carcinoma's (Huynh *et al*, 2015). Therefore, retaining functional TSC1/2-mTORC1 regulation may be beneficial for certain cancer cells (Mieulet & Lamb, 2010). An important role of TSC1/2 in metabolic homeostasis was revealed in hematopoietic stem cells (HSCs) where deletion of TSC1 results in elevated mTORC1 activity and increased ROS production with detrimental effects on HSC function and survival (Chen *et al*, 2008). A database survey revealed that TSC1-mRNA expression is the highest in Burkitt's lymphoma-derived cell lines compared to 36 different tumor-type cell lines in the Cancer Cell Line Encyclopedia (CCLE; <http://www.broadinstitute.org/ccle>) (Fig EV1A). Moreover, the COSMIC database (<http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/>) lists no mutations for TSC1 or TSC2 in Burkitt's lymphoma and they are not under the recurrently mutated genes in Burkitt's lymphoma identified by genomic approaches in two studies (Richter *et al*, 2012; Schmitz *et al*, 2012). Burkitt's lymphoma is an aggressively growing malignancy characterized by a MYC translocation that induces very high expression levels of the proto-oncogenic transcription factor MYC (Molyneux *et al*, 2012). MYC promotes cell proliferation by multiple mechanisms including stimulation of cell cycle progression, ribosome biogenesis, tRNA synthesis, translation and metabolic adjustments to increase provision of metabolic intermediates (Dang, 2012).

In this study, we reveal that MYC stimulates the expression of the mTORC1-inhibitor TSC1 by a feed-forward mechanism combining TSC1 transcriptional activation and alleviation of microRNA miR-15a-mediated repression. Loss of TSC1 function in Burkitt's lymphoma cells results in enhanced mitochondrial respiration and accumulation of toxic ROS levels. Our study is the first to provide evidence that TSC1 has tumor maintenance function designating the TSC1/2-mTORC1 axis as a novel therapeutic target in MYC-driven Burkitt's lymphoma.

¹ European Research Institute for the Biology of Ageing, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

² Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena, Germany

³ Institute for Pathology, Jena University Hospital, Jena, Germany

⁴ Center for Molecular Biomedicine, Friedrich Schiller University, Jena, Germany

⁵ Department of Pathology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

*Corresponding author. Tel: +31 6 52 72 45 91; Fax: +31 50 361 73 10; E-mail: c.f.calkhoven@umcg.nl

Results

MYC controls mTORC1 through upregulation of TSC1/2 in Burkitt's lymphoma

To examine a potential MYC-TSC1 regulation in Burkitt's lymphoma (BL), we analyzed TSC1/2 expression in human BL cell lines, which express high levels of MYC, in comparison with low MYC expressing

Hodgkin lymphoma (HL) cell lines. Immunoblotting revealed that high expression of TSC1/2 correlates with high MYC expression in BL cells and that low TSC1/2 expression correlates with low MYC in HL cells (Fig 1A). To investigate MYC-TSC1/2-mTORC1 regulation, we used the EBV immortalized human B-cell line P493-6 that carries a conditional, tetracycline-repressible MYC allele to study MYC-induced B-cell proliferation (Pajic *et al*, 2000). Also in this system, high MYC levels correlate with high TSC1/2 levels, and suppression of MYC




Figure 1. MYC controls mTORC1 signaling through regulation of the TSC1.

- A Immunoblot of expression levels of MYC, TSC1, TSC2, and β -actin loading control in high MYC Burkitt's lymphoma (BL) cells compared to low MYC Hodgkin lymphoma (HL) cells.
- B Immunoblots showing expression levels of MYC, TSC1, TSC2, or β -actin loading control in P493-6 cells treated with tetracycline for 72 hours (+Tet) or in untreated cells (-Tet).
- C Relative TSC1 and TSC2 mRNA expression levels determined by qRT-PCR for high MYC (-Tet) versus low MYC (+Tet) P493-6 cells treated for 24 h with tetracycline (mean \pm SD, $n = 3$ technical replicates). * $P < 0.05$; ** $P < 0.01$; statistical relevance was determined by unpaired t-test (two-tailed).
- D qRT-PCR analysis of TSC1 mRNA levels upon MYC suppression for 24 h–72 h (+Tet). Immunoblots for 24 h and 48 h (+Tet) show S6K and phosphorylation (P-) of S6K as downstream mTORC1 target, and β -actin loading control. For 72 h (+Tet), the immunoblots show expression of MYC and phosphorylation (P-) of downstream mTORC1 targets S6K and S6, and α -tubulin as loading control.
- E Upper immunoblot shows the reduction in TSC1 levels upon expression of two different TSC1-specific shRNAs compared to scrambled control shRNA in P493-6 cells. Other blots show the expression levels of TSC2, S6K/P-S6K, S6/P-S6, and α -tubulin for loading control.
- F Immunoblots of indicated proteins in P493-6 cells with high MYC (-Tet, 72 h) or low MYC (+Tet, 72 h) levels either treated with rapamycin or solvent.

(+Tet, 72 h) resulted in a reduction of TSC1 and TSC2 (Fig 1B). Quantitative real-time PCR (qRT-PCR) analysis revealed a strong reduction of *TSC1* mRNA versus a minor reduction of *TSC2* mRNA following 24-h repression of MYC (+Tet; Fig 1C). In addition, the decline in TSC1 protein occurred prior to the TSC2 reduction at the earlier 24-h time point (Fig EV1B). Since TSC1 stabilizes TSC2, these data suggest that low MYC levels primarily affect TSC1 expression followed by destabilization of TSC2. TSC1/2 is the major inhibitor of mTORC1 signaling and accordingly expression of high levels of MYC (–Tet) in P493-6 cells resulted in a strong reduction of phosphorylation of the mTORC1 substrate p70-S6-kinase1 (S6K) and its substrate ribosomal protein S6 measured over 24–72 h (Fig 1D). Knockdown of *TSC1* in MYC expressing P493-6 (–Tet) resulted in lower levels of TSC2 and in stimulation of mTORC1 signaling, revealing integral MYC-TSC1/TSC2-mTORC1 regulation (Fig 1E). The phosphorylation of S6K and S6 in the low MYC (+Tet) cells is abrogated by rapamycin showing that the observed effects are mTORC1 linked (Fig 1F).

Next, we analyzed the expression of MYC and TSC1 by immunohistochemistry of human BL tissue samples versus control reactive lymph node tissue samples. We found significantly higher expression of MYC and TSC1 protein levels in the BL samples compared to the B lymphocytes that reside in the germinal centers of control lymph nodes (Figs 2A and EV2A and E). In addition, in a second cohort of BL patient samples, we found significantly higher expression of TSC1 and TSC2 proteins by immunoblotting in BL compared to control tonsils and reactive lymph nodes (LN) (Figs 2B and EV2B). Thus, our results show that high TSC1/2 expression

correlates with high MYC expression in BL and BL cell lines. Finally, S6K-phosphorylation levels as determined by immunoblotting were lower for BL patient samples compared to reactive lymph node controls (Fig EV2C). S6-phosphorylation was virtually absent in seven BL tissue samples and present in one BL sample. In the reactive control lymph nodes, S6-phosphorylation staining was observed in a mosaic fashion and with different intensities (Fig EV2D and F).

Altogether, our data show that TSC1/2 expression is remarkably high in MYC BL systems and suggesting that during oncogenesis MYC maintains control of mTORC1 signaling through stimulation of TSC function.

Loss of TSC1 function is lethal for MYC-driven cancer cells

Given the anticipated role of TSC1 as a tumor suppressor, these rather unexpected findings led us to examine whether TSC1 upregulation is required for the oncogenic potential of MYC in the cellular BL model. Strikingly, *TSC1* knockdown in high (–Tet) MYC P493-6 cells resulted in a strong decrease in viable cell numbers (Fig 3A, left graph). AnnexinV/7AAD staining revealed that apoptosis was increased in *TSC1* knockdown cells (Fig 3A, right graph), suggesting that the upregulation of TSC1 by MYC is required for cell survival. Notably, the decreased P493-6 cell viability in response to *TSC1* knockdown could be rescued by treatment with the mTORC1 inhibitor rapamycin, showing that enhanced mTORC1 activity is responsible for the increased apoptosis (Fig 3B). To further analyze a potential synthetic lethal interaction between MYC deregulation and




Figure 2. Levels of TSC1 and MYC correlate in Burkitt's lymphoma.

A Elevated TSC1 and MYC expression in BL (cohort 1). Example of immune staining of TSC1, MYC, the B-cell marker CD20, and DAPI nuclear DNA-staining in germinal centers of control lymph nodes (upper rows) and samples from BL patients (lower rows). Boxplots at the right show quantification of TSC1 or MYC staining from control germinal centers and BL samples (see materials and methods; the horizontal line shows the median, whiskers show maximum and minimum data points, and the box represents the first to the third quartiles, $n = 56$ fields for tumor samples and $n = 21$ fields for control germinal centers; scale bar = 100 μm).

B Quantification of immunoblot analysis of TSC expression in BL (cohort 2) ($n = 13$) compared to healthy tonsils ($n = 3$) or reactive lymph nodes ($n = 3$) (mean \pm SD) shown in Fig EV2B.

Data information: In all graphs $*P < 0.05$; $**P < 0.01$; $***P < 0.001$, statistical relevance was determined by unpaired t-test (two-tailed).

mTORC1 hyperactivation, we made use of an U2OS cell line expressing a MYC-ER fusion protein (Liu *et al*, 2012). In cells with physiological MYC activity (–OHT), the activation of mTORC1 through knockdown of *TSC1* had little effect on cell viability. However, the combined activation of MYC (+OHT) and mTORC1 (*TSC1* knockdown) synergistically increased apoptosis, which could be prevented with rapamycin treatment (Figs 3C and EV3A). This shows that cells with deregulated MYC require restriction of mTORC1 signaling for survival and that TSC inhibition is synthetic lethal with MYC overexpression.

In order to have a better representation of the human disease, we studied the effect of *TSC1* knockdown on viability for BL cell lines. *TSC1* knockdown reduced cell viability of all eight tested BL cell lines (Fig 3D; see Figs EV3B–E and EV4D–E for *TSC1* knockdown). *TSC1* knockdown does not reduce cell viability in the low MYC and low *TSC1* Hodgkin lymphoma (HL) cell lines KMH2 and L540 (Fig EV3F). The data suggest that high expression of *TSC1* is a specific requirement for BL cells to maintain cell survival. To investigate whether loss of *TSC2* as the other part of the *TSC1/2* complex similarly affects cell survival, we knocked down *TSC2* in three selected BL cell lines. In all three cell lines, *TSC2* knockdown resulted in increased S6K-phosphorylation and reduced cell viability (Fig EV3G). Our findings may seem to be at odds with studies showing that mTORC1 signaling is required for survival of lymphomas in the Eμ-Myc mouse model (Wall *et al*, 2013) or in TCF3-activated tonic BCR signaling that activates mTORC1 (Schmitz *et al*, 2012). Therefore, we hypothesized that maintaining control of mTORC1 to prevent hypo- as well as hyperactivity is important for Burkitt's lymphoma survival. To test this hypothesis, we performed a rapamycin titration experiment using the BL cell lines BL2, DG75, and Raji. As expected, strong inhibition of mTORC1 with a high dose of rapamycin (10 nM) severely reduced the cell viability in both control and *TSC1* knockdown cells. In contrast, the decreased viability of the *TSC1* knockdown cells was recovered by treatment with low dose of rapamycin (30 pM), which titrated the mTORC1 activity to comparable levels of that in control cells (Figs 3E and

EV3H). Thus, a controlled level of mTORC1 activity that is in equilibrium with MYC expression levels is critical for the survival of BL cells and probably other MYC-driven cancer cells.

To determine whether *TSC1* function is crucial for BL tumor growth *in vivo*, we established xenotransplant models of the aggressive human Ramos BL cell line in NOD/SCID mice. Ramos cells stably expressing either a control shRNA or a *TSC1*-specific shRNA were injected subcutaneously into NOD/SCID mice and tumor growth was monitored. 35 days after cell injection, tumors derived from *TSC1* knockdown cells showed a reduced tumor volume to 43% compared to tumors derived from the control shRNA expressing cells (Fig 3F). These data indicate that knockdown of *TSC1* significantly slows BL tumor growth *in vivo*.

Loss of *TSC1* results in toxic ROS production

Next, we addressed what causes the reduced cell viability by *TSC1* knockdown. Hyperactivation of mTORC1 in certain cell types results in suppression of AKT kinase activity through negative feedback, which is reflected by the hypophosphorylation of Thr308 and Ser493 (Harrington *et al*, 2004; Manning, 2004; Rozengurt *et al*, 2014). Since AKT has a known anti-apoptotic activity (Ahmed *et al*, 1997; Dudek *et al*, 1997; Kauffmann-Zeh *et al*, 1997; Kennedy *et al*, 1997), a potential inhibition of AKT could be involved in the observed cell death. However, in a panel of BL cell lines, *TSC1* knockdown either resulted in an increase in Ser493 phosphorylation or did not change Ser493 phosphorylation of AKT, while we were unable to detect any Thr308 phosphorylation in our assay (Fig EV4A). These data suggest that decreased AKT activity is not a cause for cell death following *TSC1* knockdown. The enhanced Ser493 phosphorylation of AKT might reflect a compensatory response to counteract apoptosis.

Excessive mitochondrial respiration might result in toxic levels of reactive oxygen species (ROS) and apoptosis in cancer cells (DeNicola *et al*, 2011). Since both mTORC1 and MYC are known to increase mitochondrial respiration (Li *et al*, 2005; Cunningham *et al*, 2007), we examined mitochondrial respiration and ROS

Figure 3. *TSC1* is crucial for survival of Burkitt's lymphoma (BL) cells.

- A Left graph shows the multiplication rate of P493-6 (–Tet) cells expressing either a scrambled control shRNA or a *TSC1*-specific shRNA determined by viable cell counting 3 days after seeding of equal number of viable cells (determined by Trypan blue exclusion; mean \pm SD, $n = 3$ biological replicates). Right graph shows percentage of apoptotic P493-6 (–Tet) cells expressing scrambled control shRNA or a *TSC1*-specific shRNA determined by FACS analysis of AnnexinV/7AAD-stained cells (mean \pm SD, $n = 3$ biological replicates).
- B Rapamycin treatment recovers survival of *TSC1* knockdown in P493-6 cells. Relative viable cell number counts of P493-6 (–Tet) cells expressing scrambled control shRNA or *TSC1*-specific shRNA 14 days after seeding equal number of viable cells (Trypan blue exclusion), in the presence of 30 pM rapamycin where indicated (mean \pm SD, $n = 3$ biological replicates).
- C *TSC1* knockdown is synthetic lethal with MYC deregulation. U2OS-MYC-ER cells expressing either scrambled control shRNA or *TSC1*-specific shRNA were treated with hydroxytamoxifen (4-OHT) to induce MYC and rapamycin (100 nM) where indicated. Percentage of apoptotic cells was determined with Annexin/7AAD staining 4 days after MYC induction (mean \pm SD, $n = 3$ biological replicates).
- D Survival rate of different BL cell lines upon *TSC1* knockdown. Graphs show numbers of viable cells expressing either a scrambled control shRNA or a *TSC1*-specific shRNA 3 days after seeding of equal number of viable cells (determined by Trypan blue exclusion; mean \pm SD, $n = 3$ biological replicates).
- E Immunoblots of control- or *TSC1*-shRNA expressing BL2 or DG75 cells treated with different concentrations of rapamycin to either completely inhibit mTORC1 activity (10 nM) or titrate the activity to control levels (30 pM), and survival rate of these cells over 7 days (mean \pm SD, $n = 3$ biological replicates); (BL2 cells were selected for stable knockdown with puromycin, DG75 cells without selection).
- F Ramos cells expressing either a *TSC1*-specific or a control shRNA were inoculated into NOD/SCID mice, and tumor volume was measured regularly. The immunoblot shows the level of knockdown of *TSC1* (sh-*TSC1*^b) compared to control (sh-contr), and levels of *TSC2* and phosphorylated mTORC1 target proteins before inoculation. Tumor growth curves show mean \pm SEM ($n = 8$ /group). Pictures of xenotransplanted human Ramos lymphoma tumors 35 days after inoculation. The top panels show tumors derived from Ramos cells stably expressing control shRNA (sh-contr); the lower panels show tumors derived from Ramos cells stably expressing *TSC1*-specific shRNA (sh-*TSC1*^b).

Data information: In all graphs $*P < 0.05$; $**P < 0.01$; $***P < 0.001$, $****P < 0.0001$, statistical relevance was determined by unpaired t-test (two-tailed).




Figure 3.




Figure 4. TSC1 function restricts oxidative phosphorylation and ROS production.

A, B TSC1 knockdown increases respiration in an mTORC1- and MYC-dependent manner. Rate of basal oxygen consumption in P493-6 (–Tet) cells expressing scrambled control shRNA or TSC1-specific shRNA, treated with 20 nM rapamycin for 12 h, or tetracycline to repress MYC for 48 h where indicated (A) or in response to 10 μM of the chemical uncoupler DNP to determine maximal respiration or 10 μM of the ATP synthase inhibitor oligomycin where indicated (B) (mean ± SD, n = 6 biological replicates).

C, D Ratio of mitochondrial to genomic DNA (C) and expression of cytochrome C (CYCS) or ATP5G1 mRNAs (D) determined by qRT-PCR in P493-6 (–Tet) cells expressing either scrambled control shRNA or a TSC1-specific shRNA, and treated with 20 nM rapamycin for 12 h where indicated (mean ± SD, n = 3 technical replicates).

E TSC1 knockdown results in elevated ROS levels in a MYC- and mTORC1-dependent manner. FACS analysis of DCF-DA-stained P493-6 (–Tet) cells expressing scrambled control shRNA or a TSC1-specific shRNA to evaluate ROS production and treated with 20 nM rapamycin for 12 h and tetracycline for 48 h where indicated (mean ± SD, n = 3 biological replicates).

F TSC1 knockdown results in increased phosphorylation of SAPK/JNK. Immunoblot of SAPK/JNK Thr183/Tyr185-phosphorylation in P493-6 (–Tet) cells expressing scrambled control shRNA or a TSC1-specific shRNA. α-tubulin expression serves as loading control.

G Antioxidant treatment rescues cells from death caused by TSC1 knockdown. Relative viable cell number counts of P493-6 (–Tet) cells expressing scrambled control shRNA or TSC1-specific shRNA 3 days after seeding equal number of viable cells (Trypan blue exclusion), in the presence of 10 μM of the antioxidant BHA where indicated (mean ± SD, n = 3 biological replicates).

Data information: In all graphs *P < 0.05; **P < 0.01; ***P < 0.001, statistical relevance was determined by unpaired t-test (two-tailed).

production in the cellular BL model. *TSC1* knockdown in P493-6 cells increased total oxygen consumption as well as the ratio of oxygen consumption over lactate production (as determined by acidification), which was measured with the Seahorse XF extracellular flux analyzer (Fig 4A, left graph and Fig EV4B). Treatment with rapamycin reverted these effects demonstrating the involvement of mTORC1 signaling. Suppression of MYC by tetracycline lowered oxygen consumption of both *TSC1* knockdown and control cells revealing MYC's contribution in boosting mitochondrial function (Fig 4A, right graph). In the *TSC1* knockdown cells, we detected a higher maximal respiratory capacity compared to control cells, which was determined by treatment of the cells with the decoupling drug 2,4-dinitrophenol (DNP; Fig 4B). In response to the ATPase proton channel inhibitor oligomycin, oxygen consumption was reduced to a similar extent in both the *TSC1*-shRNA and control shRNA expressing cells, demonstrating that the observed alterations in respiration are not due to proton leakage (Fig 4B). These data show that loss of *TSC1* function and the resulting increased mTORC1 activity shifts metabolism to more mitochondrial respiration. In agreement with enhanced mitochondrial oxidative function, we found an increased ratio of mitochondrial to genomic DNA upon *TSC1* knockdown (Fig 4C), indicating enhanced mitochondrial biogenesis. Moreover, mRNA expression of cytochrome C (CYCS) and the subunit ATP5G1 of the mitochondrial ATPase that are involved in oxidative phosphorylation were enhanced in *TSC1* knockdown cells (Fig 4D). These alterations were reversed by rapamycin treatment showing their dependence on mTORC1 function. To expand our study from the P493-6 model to other BL cell lines, we performed shRNA-mediated knockdown of *TSC1* in Raji (Fig EV4C and D) and DG75 (Fig EV4E) cells. This resulted in phenotypes similar to those observed in P493-6 cells including enhanced S6K-phosphorylation, increased oxygen consumption, and higher expression of CYCS and ATP5G1.

To examine whether the increased mitochondrial respiration in response to mTORC1 activation in *TSC1* knockdown cells is accompanied by increased intracellular ROS levels, we analyzed DCF-DA-stained cells by flow cytometry. Knockdown of *TSC1* resulted in an increase in oxidized and fluorescent DCF-DA compared to the control cells, indicating an increase in ROS production (Fig 4E).

In agreement with enhanced oxidative stress, the ROS-sensitive stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) was activated upon *TSC1* knockdown (Fig 4F). Notably, the increase in ROS production in P493-6 (–Tet) cells as a result of *TSC1* knockdown could be normalized to control levels by mTORC1 inhibition through rapamycin treatment or by tetracycline-mediated MYC repression (Fig 4E). Similarly, *TSC2* knockdown resulted in increased mitochondrial respiration and increased ROS levels in BL cell lines (Fig EV4F). To examine whether elevated ROS levels are responsible for the increased lethality of *TSC1* knockdown cells, we treated the cells with the antioxidant butylated hydroxyanisole (BHA). BHA treatment restored survival of high MYC expressing P493-6 cells after knockdown of *TSC1* (Fig 4G), showing that ROS production is responsible for the enhanced apoptosis.

Altogether, these data show that the combined activation of MYC and mTORC1 leads to synergistic enhancement of mitochondrial respiration, which increases ROS production to a level that induces apoptosis. To prevent cell death by metabolic overloading, MYC controls mTORC1 signaling in BL cancer cells through the upregulation of *TSC1*.

MYC induces *TSC1* involving transcription and suppression of miR15a

Finally, we set out to investigate the mechanism of *TSC1* regulation by MYC. Steady-state *TSC1* mRNA levels were increased in high MYC (–Tet) P493-6 cells compared to low MYC (+Tet) cells as determined with qRT-PCR (Fig 1C) suggesting a regulation at the level of either transcription or mRNA stability. However, pulse labeling revealed only a moderately enhanced accumulation of nascent *TSC1* mRNA over 3 h in high (–Tet) MYC cells (Fig 5A). We used TFSEARCH software (Heinemeyer *et al*, 1998) to search for potential MYC binding sites and found a single site in the proximal *TSC1*-promoter (E-box: CACGTG, pos. –317/–322). Using *TSC1*-promoter-reporter constructs, we detected activation of the *TSC1*-promoter upon coexpression of MYC in the presence of the wild-type E-box although to a lower extent as of a control E-box reporter. Mutation of the E-boxes resulted in loss of MYC-induced activation (Fig 5B). These findings are in agreement with the

Figure 5. MYC controls *TSC1* expression through transcriptional and miR-15a-mediated regulation.

- Accumulation of EU-labeled (Click-It, Invitrogen) *TSC1*-mRNA over 3 h in high MYC (–Tet) versus low MYC (+Tet) P493-6 cells (mean \pm SD, n = 3 technical replicates).
- Drawing of the *TSC1* promoter and luciferase reporter constructs with the predicted E-box (CACGTG, pos. –317/–322) indicated. Relative luciferase units (RLU) of co-transfection experiments using the indicated *TSC1*-promoter-reporters with MYC normalized to empty pcDNA3 expression vector in HeLa cells (mean \pm SD, n = 3). Immunoblot shows MYC overexpression and α -tubulin as loading control.
- TSC1* mRNA turnover determined by pulse and chase (Click-It, Invitrogen) over 8 h in P493-6 cells, either treated with tetracycline to repress MYC or left untreated (mean \pm SD, n = 3 technical replicates).
- miR-15a expression determined by qRT-PCR in P493-6 cells treated with tetracycline for 3 days (+Tet) to suppress MYC expression or in untreated (–Tet) cells (mean \pm SD, n = 3 technical replicates).
- Immunoblots showing expression levels of *TSC1*, S6K/P-S6K, and α -tubulin in P493-6 and HEK293T cells overexpressing miR-15a or a control miRNA. At the right, miR-15a overexpression was determined by qRT-PCR in P493-6 and HEK293T cells (mean \pm SD, n = 3 technical replicates).
- Immunoblot showing *TSC1* expression, S6K/P-S6K, and α -tubulin in MCF-7 cells transfected with LNA modified anti-sense miR-15a oligos or control LNAs. At the right, successful miR-15a knockdown determined by qRT-PCR in MCF-7 cells is shown (mean \pm SD, n = 3 technical replicates).
- Relative luciferase units (RLU) derived from reporter constructs containing *TSC1*-3'UTR wild-type sequences or with mutated miR-15a seed sequence binding site on co-transfection with miR-15a in MCF-7 cells (mean \pm SD, n = 3 biological replicates). The drawing at the right shows the *TSC1*-3'UTR with the position of the miR-15a/16-1 seed sequence and used mutation indicated.
- Rate of oxygen consumption in P493-6 (–Tet) cells ectopically expressing miR-15a or control miRNA vector, under basal conditions and in response to 10 μ M DNP or 10 μ M oligomycin where indicated (mean \pm SD, n = 8 biological replicates).

Data information: In all graphs * P < 0.05; ** P < 0.01; *** P < 0.001, statistical relevance was determined by unpaired t-test (two-tailed).




Figure 5.

ENCODE database that records a MYC-associated DNA fragment of intermediate signal strength covering the same sequence (<http://genome.ucsc.edu/ENCODE/>). The rather modest transcriptional regulation of *TSC1* suggested that it might not be the sole mechanism involved. Therefore, we performed a pulse-chase labeling experiment, which revealed a strongly enhanced *TSC1* mRNA turnover in low MYC (+Tet) compared to high MYC (–Tet) P493-6 cells (Fig 5C), indicating that MYC function stabilizes the *TSC1* mRNA. Since MYC is a known regulator of microRNA (miRNA) expression (Chang *et al*, 2008), we examined whether the observed increase in mRNA turnover in response to MYC repression may be caused by miRNA regulation, which generally results in deadenylation and decay of target mRNAs. In search of potentially involved miRNAs, we identified conserved binding sites for the MYC-suppressed miRNAs miR-15a/16-1, -22, -23ab -26ab, -29abc, -30e-5p, and -195 in the 3′ untranslated region (3′UTR) of the *TSC1* mRNA by using the TargetScan algorithm (www.targetscan.org). Importantly, those miRNAs are direct MYC targets and were found to be among the suppressed miRNAs in high MYC expressing BL patient samples compared to B cells from hyperplastic tonsils or samples from patients with MYC translocation negative non-Hodgkin lymphomas (NHLs), including mantle cell lymphoma (MCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL) (Robertus *et al*, 2010; Table EV1). Overexpression of single miRNAs in HEK293T cells revealed that miR-15a, miR-22, and miR-23a strongly suppressed *TSC1* and increased P-S6K with miR-15a having the strongest effect on inducing phosphorylation of S6K (Fig EV5A). MiR-15a and miR-16-1 have identical seed sequences and reside in the *DLEU2/miR-15a/16-1* cluster in the chromosomal region 13q14 whose deletion is commonly associated with the B-cell malignancy chronic lymphocytic leukemia (B-CLL; Klein *et al*, 2010). It was shown by others that MYC represses pri-microRNA 15a/16-1 transcription in P493-6 cells through direct interaction with the pri-microRNA promoter (Chang *et al*, 2008). Accordingly, we found that induction of MYC reduced miR-15a levels in P493-6 cells (Fig 5D). Overexpression of miR-15a in P493-6 and HEK293T cells resulted in decreased *TSC1* protein levels compared to the control microRNA with concomitant induction of S6K phosphorylation in both cell lines (Fig 5E). Moreover, knockdown of miR-15a in MCF-7 cells by transfection of LNA modified anti-sense miR-15a oligonucleotides resulted in elevated *TSC1* expression and reduced S6K phosphorylation compared to cells that were transfected with control LNAs (Fig 5F). Next, we examined whether miR-15a suppresses *TSC1* mRNA through direct interaction with the *TSC1*-3′UTR. Overexpression of miR-15a reduced the luciferase expression from a *TSC1*-3′UTR-driven luciferase reporter construct and mutation of the miR-15a seed sequence relieved the miR-15a-mediated repression (Fig 5G). Thus, the *TSC1* mRNA is suppressed through direct interaction with miR-15a. Although our experiments show that miR-15a is sufficient for modulation of the *TSC1*-mTORC1 axis, the other MYC-suppressed miRNAs that target *TSC1* may further solidify the regulation. Notably, oxygen consumption as well as maximal respiratory capacity was also increased in P493-6 cells that overexpress miR-15a (Fig 5H), revealing the crucial function of this miRNA in the MYC-TSC1-mTORC1 regulatory pathway and in the regulation of mitochondrial physiology. Furthermore, miR-15a overexpression decreased cell viability in two BL cells (Fig EV5B). Taken together, the results indicate that MYC augments *TSC1* expression

by a feed-forward mechanism—one of the most common motifs in transcriptional networks—combining the stimulation of *TSC1* transcription with the alleviation of miR-15a function and thereby increasing *TSC1* mRNA stability.

Discussion

The proto-oncogene MYC is often deregulated in human cancers yet therapeutic strategies to directly target MYC are currently not available. Identifying synthetic lethal interactions with oncogenic functions of MYC may lead to new therapeutic strategies. In this study, we present a connection between MYC and mTORC1 in Burkitt's lymphoma that may provide the foundation for novel therapeutic opportunities. MYC induces the expression of the mTORC1 inhibitor *TSC1* through stimulation of *TSC1* transcription and downregulation of miR-15a that targets the *TSC1*-mRNA. Other identified MYC-repressed and *TSC1*-targeting microRNAs that were not further investigated here may reinforce this regulation. The upregulation of *TSC1* by MYC results in the attenuation of mTORC1 signaling in order to safeguard mitochondrial homeostasis and thereby preventing the accumulation of toxic ROS levels. In addition, knockdown of either *TSC1* or *TSC2* results in an upregulation mTORC1 signalling, accompanied by enhanced mitochondrial respiration, elevated ROS levels, and reduced cell viability, showing that the effects are not specific for *TSC1* but related to *TSC1/2* complex function. Since *TSC1/2* is generally considered to function as a tumor suppressor (Mieulet & Lamb, 2010) and elevated mTORC1 signaling has been detected in a large proportion of human cancers including B-cell malignancies (Dazert & Hall, 2011), our finding was surprising. However, we detected elevated *TSC1/2* expression in tumors of two independent cohorts of BL patients and in several BL-derived cell lines. Furthermore, our data show that *TSC1/2* controls mTORC1 in BL and is crucial for survival in MYC overexpressing cells. Altogether, this argues against a role for *TSC1/2* in tumor suppression in human BL, but rather for a role in tumor maintenance. We propose a model for BL in which a window of mTORC1 activity that supports cell survival is controlled by MYC through maintenance of *TSC* expression (Fig 6). In spontaneously immortalized rat fibroblast (Rat1A cell lines), Myc was shown to repress *TSC2* transcription resulting in increased S6K activity and soft agar colony formation (Ravitz *et al*, 2007), which seems to be at odds with our findings. Notwithstanding, our data clearly reveal a positive correlation between high MYC and high *TSC1/2* levels in BL cell lines as well as in patient material (Figs 1A and 2), and the positive transcriptional and post-transcriptional regulation of *TSC1* transcript by MYC (Figs 1C and D, and 5A–C). Possibly, these apparently opposing results are caused by different wiring of *TSC2* regulation in fibroblasts and BL cells. In support of our finding is a study in the fly *D. melanogaster* where *TSC* was identified as an essential regulator of intestinal stem cells in the *Drosophila* midgut, using an RNAi-based genetic screen. Loss of *TSC* results in excessive cell growth and halted cell division, which is rescued by reducing Myc levels or inhibition of TORC1 by treatment with rapamycin (Amcheslavsky *et al*, 2011). The latter study and the data presented here show that at least in certain context high MYC levels are incompatible with high mTORC1 activation.

Activation of mTORC1 in cancer has been shown in numerous studies (Zoncu *et al*, 2011). mTORC1 and MYC have overlapping




Figure 6. Model of the MYC-miR-15a-TSC1 axis controlling mTORC1 activity.

Hyperactivation of mTORC1 through loss of TSC1 function results in metabolic stress, ROS production, and apoptosis. Under this condition, low dose of rapamycin restores mTORC1 levels that are compatible with cell viability.

functions, including stimulating effects on cell growth and proliferation, ribosome biogenesis, and protein synthesis. In addition, mTORC1 induces oxidative phosphorylation by facilitating YY1/PGC1 α complex formation (Cunningham *et al*, 2007) and supports aerobic glycolysis (Duvel *et al*, 2010). In the E μ -Myc mouse model, mTORC1 activation was shown to accelerate lymphomagenesis by inhibiting Myc-induced apoptosis through translational upregulation of the anti-apoptotic protein myeloid cell leukemia 1 (Mcl1; Mills *et al*, 2008), suggesting a collaboration of Myc and mTORC1 in tumor initiation. On the contrary, MYC amplification was shown to confer resistance to mTORC1 inhibition through transcriptional activation of the eukaryotic translation initiation factor 4E (eIF4E), suggesting that mTORC1 function is not critical in the context of high MYC expression (Ilic *et al*, 2011). Correspondingly, in a chemical screen study elevated MYC levels correlated with enhanced resistance to PI3K/mTORC1 inhibition (Muellner *et al*, 2011). In line with our study, others have shown that deregulation of MYC may result in energy (ATP) depletion and suppression of mTORC1 through the activation of NUA1/ARK5-AMPK, which is required for metabolic homeostasis and cell survival (Liu *et al*, 2012). However, this regulation may not be relevant for BL and other leukemia, since the CCLE data (<http://www.broadinstitute.org/ccle>) reveal that *NUA1/ARK5* mRNA expression is very low in most leukemia and lymphoma-derived cell lines, compared to cell lines derived from solid tumors (Fig EV5C). Altogether, multiple studies suggest that MYC-driven oncogenesis does not obligatory require mTORC1 activation and that time- and dose-dependent variation in mTORC1 signaling may be required for different stages of tumor development.

Our study for the first time reveals a tumor maintenance function for TSC1/2 and thereby questions the general role of the TSC1/2 complex as a tumor suppressor. Although our results point to canonical mTORC1 inhibition as being responsible for the tumor maintenance activity, we cannot rule out the involvement of other TSC1/2 functions. So far, we do not know whether the requirement of TSC1/2

for cancer cell survival is restricted to BL or whether it might be a characteristic also for other MYC-driven cancers. Nonetheless, in specific cancer (sub)-types, the inhibition of TSC1/2 function or the activation of mTORC1 may be considered for a novel therapeutic strategy.

Material and Methods

Cell culture and plasmids

P493-6, Raji, BL2, Ramos, DG75, CA46, ST486, Jiyoye, EW36, AG876, KMH2, L428, L450, L1236, and MCF-7 cells were maintained in RPMI 1640. HEK293T, U2OS-MYC-ER cells (Liu *et al*, 2012), wt MEFs, and TSC1-deficient MEFs (Hsieh *et al*, 2012) were maintained in DMEM. All media were supplemented with 10% FCS (Tet-free FCS from Clontech was used for P493-6 cells) or 15% (EW36, AG876, KMH2, L428, L450, and L1236), non-essential amino acids, and penicillin/streptomycin. For repression of MYC in P493-6 cells, 0.1 μ g/ml tetracycline was added to the culture medium, and for activation of MYC in U2OS-MYC-ER cells, the culture medium was supplemented with 100 μ M hydroxytamoxifen (4-OHT) for 4 days. Rapamycin was added in a concentration range from 30 pM to 100 nM for different time periods. For antioxidant treatment, cells were grown for 3 days in the presence of 1 μ M butylated hydroxyanisole (BHA, Sigma-Aldrich).

Transfection and transduction

HEK293T cells were seeded to a density of 2×10^6 cells in 10-cm culture dishes. 24 h later, transfection was carried out using the calcium phosphate method. pcDNA-6.2-GW/EmGFP-miRNA (Invitrogen)-based microRNA expression vectors were transfected in P493-6 cells using the Amaxa Nucleofector (Lonza) following the manufacturer's instructions, and stable microRNA expressing cell lines were obtained by selecting on blasticidin. Locked nucleic acids (LNA) anti-miR-15a and control LNAs (Exiqon) were transfected using HiPerfect (Qiagen) in 6-well plates following the manufacturer's instructions. Cells were harvested after 72 h. Transfection of P493-6 cells with self-delivery Accell siRNAs (Dharmacon) was performed according to the provider's instructions in 96-well plates. MicroRNA expression vectors were generated using the Block-it system (Invitrogen) using the pcDNA-6.2-GW/EmGFP-miR- vector. Cells were infected following a standard protocol with pLKO.1 lentiviral constructs containing shRNAs against human *TSC1*: sh-a 5'-CCG GGC ACT CTT TCA TCG CCT TTA TCT CGA GAT AAA GGC GAT GAA AGA GTG CTT TTT G-3'; sh-b 5'-CCG GGC CAA GAA AGA CCA CCT TCT TCT CGA GAA GAA GGT GGT CTT TCT TGG CTT TTT G-3', *TSC2*: 5'-CCG GGC TCA TCA ACA GGC AGT TCT ACT CGA GTA GAA CTG CCT GTT GAT GAG CTT TTT G-3' and *MYC*: 5'-CCG GCC TGA GAC AGA TCA GCA ACA ACT CGA GTT GTT GCT GAT CTG TCT CAG GTT TTT G-3' or non-target shRNA control (Sigma-Aldrich). Stable shRNA expressing cells were obtained by selection on puromycin.

MicroRNA expression plasmids

MicroRNA expression vectors were generated using the Block-it system (Invitrogen). Briefly, oligos were phosphorylated, annealed,

and ligated with the pcDNA-6.2-GW/EmGFP-miR- vector following the manufacturer's instructions. The following oligos were used for ligation: miR-15a 5'-TGC TGT AGC AGC ACA TAA TGG TTT GTG GTT TTG GCC-3' (top strand) and 5'-ACT GAC TGA CCA CAA ACC TAT GTG CTG CTA-3' (bottom strand), miR-22 5'-TGC TGA AGC TGC CAG TTG AAG AAC TGT GTT TTG GCC ACT GAC TGA CAC AGT TCT AAC TGG CAG CTT-3' (top strand) and 5'-CCT GAA GCT GCC AGT TAG AAC TGT GTC AGT CAG TGG CCA AAA CAC AGT TCT TCA ACT GGC AGC TTC-3' (bottom strand), miR-23a 5'-TGC TGA TCA CAT TGC CAG GGA TTT CCG TTT TGG CCA CTG ACT GAC GGA AAT CCG GCA ATG TGA T-3' (top strand) and 5'-CCT GAT CAC ATT GCC GGA TTT CCG TCA GTC AGT GGC CAA AAC GGA AAT CCC TGG CAA TGT GAT C-3' (bottom strand), miR-26a 5'-TGC TGT TCA AGT AAT CCA GGA TAG GCT GTT TTG GCC ACT GAC TGA CAG CCT ATC GGA TTA CTT GAA-3' (top strand) and 5'-CCT GTT CAA GTA ATC CGA TAG GCT GTC AGT CAG TGG CCA AAA CAG CCT ATC CTG GAT TAC TTG AAC-3' (bottom strand), miR-29a 5'-TGC TGT AGC ACC ATC TGA AAT CGG TTA GTT TTG GCC ACT GAC TGA CTA ACC GAT CAG ATG GTG CTA-3' (top strand) and 5'-CCT GTA GCA CCA TCT GAT CGG TTA GTC AGT CAG TGG CCA AAA CTA ACC GAT TTC AGA TGG TGC TAC-3' (bottom strand), miR-30e 5'-TGC TGT GTA AAC ATC CTT GAC TGG AAG GTT TTG GCC ACT GAC TGA CCT TCC AGT AGG ATG TTT ACA-3' (top strand) and 5'-CCT GTG TAA ACA TCC TAC TGG AAG GTC AGT CAG TGG CCA AAA CCT TCC AGT CAA GGA TGT TTA CAC-3' (bottom strand), and a non-targeting miRNA was used as a control (Invitrogen).

Immunoblotting

Immunoblotting was performed as described earlier (Zidek *et al*, 2015) with the following antibodies: from Cell Signaling Technology, anti-TSC1 (#4906), anti-TSC2 (#4308); anti-pS6K (Thr389) (#9206) and (Thr389) (#9234), anti-S6K (#9202), anti-pS6 (Ser235/236) (#2211), anti-S6 (#2317), anti-pSAPK/JNK (Thr183/Tyr185) (#9251); anti-p-4E-BP1 (T37/46) (#9459); anti-p-AKT (Ser473) (#4060); anti-AKT (#9272); anti-MYC (#5605); from Sigma-Aldrich, anti- β -actin (A3853); from Santa Cruz Biotechnology, anti- α -tubulin (sc-8035), anti-TSC2 (sc-893), anti-MYC (sc-40), anti-SAPK/JNK (sc-571); and from MP Biomedicals, anti- β -actin (#69100). Bands were visualized by chemoluminescence (Western Lightning Plus-ECL, Perkin Elmer).

qRT-PCR

RNA was isolated using the RNeasy kit (Qiagen), and cDNA synthesis was done using the first strand cDNA kit (ROCHE). qRT-PCR was performed on a LC480 Light Cycler (Roche) using SYBR Green (Roche) and the following primers: TSC1 5'-CAA ACT CCA GGC AAG AGG AC-3' (forward) and 5'-CCA ATT CAA ACA CCT GGG TTA-3' (reverse), TSC2 5'-TGC AAG CCG TCT TCC ACA T-3' (forward) and 5'-ATG GAC ACA AAG TCG TTG C-3', β -actin 5'-AGA GGG AAA TCG TGC GTG AC-3' (forward) and 5'-CAA TAG TGA TGA CCT GGC CGT-3' (reverse), ATP5G1 5'-AGG GCT AAA GCT GGG AGA CTG AA-3' (forward) and 5'-GTC TGG CCA CCT GGA GTG GGA-3' (reverse), CYCS 5'-AGG GAC AGA ATT TAA ATA TGG GTG A-3' (forward) and 5'-AGA TTT GGC CCA GTC TTG TG-3' (reverse), HPRT (for normalization) 5'-TGA CAC TGG CAA AAC AAT GCA-3' (forward) and 5'-GGT CCT TTT CAC CAG CAA GCT-3'

(reverse). For microRNA qRT-PCR, RNA was isolated using the miRNeasy kit (Qiagen), and primers obtained from the miScript System (Qiagen) were used for expression analysis with a primer for U6 RNA used for normalization. Primers for the analysis of mitochondrial DNA to genomic DNA ratio: genomic glucagon-intron 5'-TGA CAA AGA CGG ACT TGA CG-3' (forward) and 5'-CCC TGT GTC ACA AGC AGA TG-3' (reverse); mitochondrial COX2 5'-TTC ATG ATC ACG CCC TCA TA-3' (forward) and 5'-TAA AGG ATG CGT AGG GAT GG-3' (reverse).

mRNA labeling experiments

TSC1 nascent transcription or mRNA stability was determined using the Click-It Nascent RNA Capture Kit (Invitrogen) according to the protocol of the manufacturer. P493-6 cells were grown for 3 days in the absence or presence of tetracycline. Cells were seeded in a concentration of 1×10^6 cells/ml growth medium (RPMI), and mRNA was labeled with 5-ethynyl uridine (EU) in a final concentration of 200 μ M in the absence or presence of tetracycline. Cells were harvested after 3-h labeling for analysis of initial transcription rates. For pulse chase, cells were labeled o.n., washed twice with PBS, and chased for different time points with normal growth medium in the absence or presence of tetracycline. Non-labeled cells were used as control (for each time point, 1.5×10^7 cells were used). Total RNA was prepared using the RNeasy kit from Qiagen, and 2 μ g RNA was biotinylated using 0.5 mM biotin azide. After RNA precipitation, the biotinylated RNA was isolated using Streptavidin T1 magnetic beads and used for cDNA synthesis using the SuperScript Reverse Transcriptase (Roche). The amount of biotinylated hTSC1 mRNA was determined by qRT-PCR on a LC480 Light Cycler (Roche) and normalized to β -actin mRNA levels.

Luciferase assay

Luciferase constructs were obtained by cloning TSC1-3'UTR sequence containing miR-15a binding site into pGL3 Vector (Promega). Briefly, 3'UTR sequence was PCR amplified using the following primers: 5'-ATG CTC TAG ATC TGC TGC ACC TTC ACT CTC-3' (forward) and 5'-ATG CTC TAG AGC AAA ATC TGT TCC TCC GTA A-3' (reverse), XbaI digested and ligated into the XbaI restriction site of the pGL3-promoter vector. For site-directed mutagenesis of the miR-15a binding site by PCR, the following primers were used: 5'-GAC AGG AGG TAT GGC GAT CCT CTG TGT AGC A-3' (forward) and 5'-TGC TAC ACA GAG GAT CGC CAT ACC CTC CTG TC-3' (reverse). For the luciferase assay, 2×10^4 MCF-7 cells per well were seeded into 96-well plates. After 24 h, cells were co-transfected with TSC1-3'UTR-pGL3 luciferase reporter, Renilla reporter, and either miR-15a or control pcDNA-6.2-GW/EmGFP-miRNA expression vectors. After additional 24 h, luciferase activity was measured using the Stop and Glow kit (Promega) following the manufacturer's protocol with a Mithras LB 940 (Berthold technologies).

For generating the TSC1-promoter luciferase reporters, TSC1 promoter fragments were amplified by PCR from genomic DNA using following forward primers: E1^{wt} 5'-GCG GGT ACC GGG CGC TCC AAC CAC ACC CAG-3', in combination with the reverse primer 5'-GCG CTC GAG CTT GGA CGT ACA GCA CCT CCC-3'. The mutation of E-box (E1^{mut}) was performed by PCR using the forward primer for E1^{wt} and the reverse primer as outer primers, and the

primers: 5'-CCG CCC GCC AGT CAC CCG ACC GCC CGC CCC-3' and 5'-GGG GCG GGC GGT CCG GTG ACT GGC GGG CGG-3' carrying the mutation. PRC fragments were digested with KpnI and XhoI and cloned into the pGL3-Basic Firefly luciferase vector (Promega). The pTK-Ap2/E (renamed in E-box^{Rep}) and pTK-AP2/mut4 (renamed in E-box^{RepMut}) E-box luciferase reporter constructs were obtained from Martin Eilers (Gaubatz *et al*, 1995). 20 h before transfection, HeLa cells were seeded in a 96-well plate (5,000 cells per well). Transfection was performed in triplicates using 100 ng pGL4 Renilla vector, 300 ng Firefly reporter, and either 600 ng pcDNA3, 600 ng pCMV-Myc, and 3 μ l Eugene (Promega) according to the protocol of the manufacturer. 5 h after transfection, medium was exchanged, and luciferase activity was analyzed 48 h after transfection by using the Stop and Glow kit (Promega) with a Mithras LB 940 (Berthold Technologies).

Measurement of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR)

To measure the rate change of dissolved oxygen (oxygen consumption rate) in the culture medium, a Seahorse XF96 was used. To calculate the ratio of oxygen consumption over lactate production, the pH change in the medium (acidification rate as indirect method for lactate production) was measured simultaneously. Between 4×10^4 and 8×10^4 cells were seeded in unbuffered DMEM in polylysine treated XF96 plates 1 h prior to the assay, and the measurement was made over 2 min. Rapamycin (20 nM) treatment was done for 12 h prior to the measurement. Concentrations of the injected drugs were as follows: oligomycin (10 μ M), 2,4-dinitrophenol (DNP) (10 μ M), FCCP (600 nM), all from Sigma-Aldrich.

Apoptosis assay and ROS measurement

To determine apoptosis, the AnnexinV/7AAD Apoptosis detection kit from BD Biosciences was used. Cells were treated according to the manufacturer's protocol and analyzed by FACS using a BD FACSCanto II. For cell multiplication, equal number of viable cells (Trypan blue exclusion) were seeded and assayed for viability 3 days after seeding, using a cell viability assay from Promega (Cell-Titer Glo). For ROS measurements, cells were incubated with 10 μ M DCF-DA (Sigma-Aldrich) or 5 μ M CellRox (Invitrogen) for 30 min under normal culture conditions, washed and subjected to FACS analysis using a BD FACSCanto II.

Tumor xenotransplant mouse studies

4.5×10^6 Ramos cells, expressing either a scrambled shRNA or a shRNA against TSC1 (titer 1×10^8 , MISSION shRNAs, Sigma), were inoculated into immunodeficient NOD/SCID mice ($n = 8$ /group) subcutaneously, and tumor growth was monitored over time. Tumor volume was calculated in all experiments according to $V = (\text{length} \times \text{width}^2)/2$, and animals were sacrificed when tumor size exceeded 2 cm³. Mice experiments were performed by EPO GmbH (Berlin, Germany) according to the German Animal Protection Law with permission of the responsible authorities. Statistical significance was determined by unpaired *t*-test (two-tailed). The experiment was not randomized. The investigators were not blinded to allocation during the experiment.

Tissue samples

Individual diagnoses were reviewed by an experienced hematopathologist for consistent morphology and immunophenotype according to the 2008 WHO classification (Swerdlow *et al*, 2008). Pediatric BL presented with abdominal mass and was CD10⁺, BCL2⁻, and MYC/8q24 breakpoint positive. All protocols for obtaining human tissue samples were performed in accordance to the guidelines from the Institutional Review Board or Medical Ethical Committee of the University Medical Center Groningen and University Hospital Jena.

Histological analysis

Lymph node and Burkitt's lymphoma (BL) tissue sections were deparaffinized; heat-mediated antigen retrieval was done in citrate buffer for 15 min at the sub-boiling point. Sections were cooled down to room temperature, washed three times with PBS, and were then blocked with 2% BSA in PBS for 1 h at room temperature. Primary antibody was incubated in 1% BSA, in a humidified chamber o.n. at 4°C with the following dilutions: TSC1 (Abcam, ab 40872) 1:75, CD20 (Abcam, ab 9475) 1:20, MYC (Abcam, ab 39688) 1:50, P-S6 (Ser235/236) (Cell Signaling Technology, #4857) 1:75. Sections were washed with PBS and incubated with the fluorescence-conjugated secondary antibody (Alexa Fluor 488 goat anti-rabbit or Alexa Fluor 568 goat anti-mouse, Invitrogen) in 1% BSA for 2 h at room temperature. After washing with PBS, sections were sealed with coverslips in diamine phenylindole (DAPI) containing mounting medium (Fluoroshield, ImmunoBioScience Corp.). Microscopic analysis was performed with the Zeiss AxioImager Z1 microscope. For the quantification of TSC1 and MYC staining in CD20-positive B cells, images (200 \times magnified) of seven follicles of the superficial cortex of three control lymph nodes each (21 images) were compared with seven images taken from eight BL samples derived from different sites, lymph node (4 \times), cerebellum (1 \times), bone marrow (1 \times), oropharynx (1 \times), nasopharynx (1 \times). Analysis was performed using CellProfiler (Carpenter *et al*, 2006). Nuclei were visualized by the DAPI staining, and the cell outline was identified from the TSC1 staining. The TSC1-positive cytoplasm was identified by subtracting the nuclear area from the cell outline, and TSC1 fluorescence intensities were measured in the cytoplasm of an average of 1,500 cells per image. Statistical significance of mean fluorescence intensities was tested with the *t*-test (unpaired, two-tailed) using R (R Development Core Team (2008). "R: A Language and Environment for Statistical Computing". from <http://www.R-project.org>).

Expanded View for this article is available online.

Acknowledgments

We thank Dirk Eick from the Helmholtz Centre Munich for the P493-6 cells, Daniel Murphy from the University of Glasgow for the U2OS-MYC-ER cells and helpful discussions, Marieke von Lindern from Sanquin in Amsterdam for the TSC1, TSC2, MYC, and control shRNA vectors, Martin Eilers from the Theodor Boveri Institute of the University of Würzburg for MYC expression vector, the pTK-Ap2/E and pTK-AP2/mut4 E-box-containing reporter constructs and advise on the related experiments. From the Friedrich Schiller University of Jena, we thank Berit Jungnickel for the BL2, Ramos, and DG75 cells, and Kim Zarse and Michael Ristow for advise on the experiments with antioxidants. At the FLI, we

thank Annemarie Carlstedt for technical assistance, Simone Tänzer, Anne Gompf, and Ulrike Baschant for help with FACS, and Kristin Dreffeke for providing the apoptosis assay protocol. J.K. and A. vd B. were supported by the Pediatric Oncology Foundation Groningen (#SKOG 11-001). G.H. was supported by the Deutsche Krebshilfe e.V. through a grant (#110193) to C.F.C. G.H. and A.K. were supported by the Leibniz Graduate School on Ageing and Age-Related Diseases (LGSA; www.fli-leibniz.de/phd/), and L.M.Z. was supported by the Deutsche Forschungsgemeinschaft through a grant (CA 283/1-1) to C.F.C. C.M. and G.K. are supported by the KWF kankerbestrijding (Dutch Cancer Society) to a grant to C.F.C. (KWF 11010).

Author contributions

CFC supervised the project. GH and CFC conceived and designed the study. GH, CM, AK, LMZ, CD, RW, SE, and GK performed experiments. HS, JK, IP, and AB provided patient materials and advised on Burkitt's lymphoma. CK and Z-QW provided recourses for and advised on mouse experiments. GH, CM, JK, AB, and CFC were involved in writing the paper.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tschlis PN (1997) Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. *Proc Natl Acad Sci USA* 94: 3627–3632
- Amcheslavsky A, Ito N, Jiang J, Ip YT (2011) Tuberous sclerosis complex and Myc coordinate the growth and division of *Drosophila* intestinal stem cells. *J Cell Biol* 193: 695–710
- Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM (2006) Cell Profiler: image analysis software for identifying and quantifying cell phenotypes. *Genome Biol* 7: R100
- Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT (2008) Widespread microRNA repression by Myc contributes to tumorigenesis. *Nat Genet* 40: 43–50
- Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, Zheng P (2008) TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. *J Exp Med* 205: 2397–2408
- Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P (2007) mTOR controls mitochondrial oxidative function through a YY1-PGC-1 α transcriptional complex. *Nature* 450: 736–740
- Dang CV (2012) MYC on the path to cancer. *Cell* 149: 22–35
- Dazert E, Hall MN (2011) mTOR signaling in disease. *Curr Opin Cell Biol* 23: 744–755
- DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. *Nature* 475: 106–109
- Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. *Science* 275: 661–665
- Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. *Mol Cell* 39: 171–183
- Gaubatz S, Imhof A, Dosch R, Werner O, Mitchell P, Buettner R, Eilers M (1995) Transcriptional activation by Myc is under negative control by the transcription factor AP-2. *EMBO J* 14: 1508–1519
- Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. *J Cell Biol* 166: 213–223
- Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV, Ignatieva EV, Ananko EA, Podkolodnaya OA, Kolpakov FA, Podkolodny NL, Kolchanov NA (1998) Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. *Nucleic Acids Res* 26: 362–367
- Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. *Nature* 485: 55–61
- Huynh H, Hao HX, Chan SL, Chen D, Ong R, Soo KC, Pochanard P, Yang D, Ruddy D, Liu M, Derti A, Balak MN, Palmer MR, Wang Y, Lee BH, Sellami D, Zhu AX, Schlegel R, Huang A (2015) Loss of tuberous sclerosis complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus. *Mol Cancer Ther* 14: 1224–1235
- Ilic N, Utermark T, Widlund HR, Roberts TM (2011) PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. *Proc Natl Acad Sci USA* 108: E699–E708
- Kauffmann-Zeh A, Rodriguez-Viciano P, Ulrich E, Gilbert C, Coffey P, Downward J, Evan G (1997) Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. *Nature* 385: 544–548
- Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tschlis PN, Hay N (1997) The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. *Genes Dev* 11: 701–713
- Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, Ambesi-Impimbato A, Califano A, Migliozza A, Bhagat G, Dalla-Favera R (2010) The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. *Cancer Cell* 17: 28–40
- Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, O'Donnell KA, Kim JW, Yustein JT, Lee LA, Dang CV (2005) Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. *Mol Cell Biol* 25: 6225–6234
- Liu L, Ulbrich J, Muller J, Wustefeld T, Aeberhard L, Kress TR, Muthalagu N, Rycak L, Rudalska R, Moll R, Kempa S, Zender L, Eilers M, Murphy DJ (2012) Deregulated MYC expression induces dependence upon AMPK-related kinase 5. *Nature* 483: 608–612
- Manning BD (2004) Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. *J Cell Biol* 167: 399–403
- Mieulet V, Lamb RF (2010) Tuberous sclerosis complex: linking cancer to metabolism. *Trends Mol Med* 16: 329–335
- Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, Trojahn U, Wendel HG, Charest A, Bronson RT, Kogan SC, Nadon R, Housman DE, Lowe SW, Pelletier J (2008) mTORC1 promotes survival through translational control of Mcl-1. *Proc Natl Acad Sci USA* 105: 10853–10858
- Molyneux EM, Rochford R, Griffin B, Newton N, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S (2012) Burkitt's lymphoma. *Lancet* 379: 1234–1244
- Muellner MK, Uras IZ, Gapp BV, Kerzendorfer C, Smida M, Lechtermann H, Craig-Mueller N, Colinge J, Duernberger G, Nijman SM (2011) A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. *Nat Chem Biol* 7: 787–793

- Pajic A, Spitkovsky D, Christoph B, Kempkes B, Schuhmacher M, Staeger MS, Briemeier M, Ellwart J, Kohlhuber F, Bornkamm GW, Polack A, Eick D (2000) Cell cycle activation by c-myc in a burkitt lymphoma model cell line. *Int J Cancer* 87: 787–793
- Pymar LS, Platt FM, Askham JM, Morrison EE, Knowles MA (2008) Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. *Hum Mol Genet* 17: 2006–2017
- Ravitz MJ, Chen L, Lynch M, Schmidt EV (2007) c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation. *Cancer Res* 67: 11209–11217
- Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH, Lenze D, Szczepanowski M, Paulsen M, Lipinski S, Russell RB, Adam-Klages S, Apic G, Claviez A, Hasenclever D, Hovestadt V et al (2012) Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. *Nat Genet* 44: 1316–1320
- Robertus JL, Kluiver J, Weggemans C, Harms G, Reijmers RM, Swart Y, Kok K, Rosati S, Schuurin E, van Imhoff G, Pals ST, Kluin P, van den Berg A (2010) MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. *Br J Haematol* 149: 896–899
- Rozengurt E, Soares HP, Sinnett-Smith J (2014) Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. *Mol Cancer Ther* 13: 2477–2488
- Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Muller-Hermelink HK, Ott G et al (2012) Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature* 490: 116–120
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (2008) *WHO classification of tumours of haematopoietic and lymphoid tissues*. Lyon: IARC
- Wall M, Poortinga G, Stanley KL, Lindemann RK, Bots M, Chan CJ, Bywater MJ, Kinross KM, Astle MV, Waldeck K, Hannan KM, Shortt J, Smyth MJ, Lowe SW, Hannan RD, Pearson RB, Johnstone RW, McArthur GA (2013) The mTORC1 inhibitor everolimus prevents and treats Emu-Myc lymphoma by restoring oncogene-induced senescence. *Cancer Discov* 3: 82–95
- Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. *Nat Rev Mol Cell Biol* 12: 21–35
- Zidek LM, Ackermann T, Hartleben G, Eichwald S, Kortman G, Kiehnopf M, Leutz A, Sonenberg N, Wang Z-Q, von Maltzahn J, Müller C, Calkhoven CF (2015) Deficiency in mTORC1-controlled C/EBP β -mRNA translation improves metabolic health in mice. *EMBO Reports* 16: 1022–1036



License: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.